Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

Ricardo Costa1
Benedito A Carneiro1,2
Sunandana Chandra1,2
Sachin G Pai1
Young Kwang Chae1,2
Jason B Kaplan1,2
Hannah B Garrett1
Mark Agulnik1,2
Peter A Kopp1
Francis J Giles1,2

1Northwestern Medicine
Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, 2Division of Hematology and Oncology, Feinberg School of Medicine, 3Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

Abstract: Thyroid cancer is the most common endocrine malignancy, with over 60,000 cases reported per year in the US alone. The incidence of thyroid cancer has increased in the last several years. Patients with metastatic differentiated thyroid cancer (DTC) generally have a good prognosis. Metastatic DTC can often be treated in a targeted manner with radioactive iodine, but the ability to accumulate iodine is lost with decreasing differentiation. Until recently, chemotherapy was the only treatment in patients with advanced thyroid cancer, which is no longer amenable to therapy with radioactive iodine. The modest efficacy and significant toxicity of chemotherapy necessitated the need for urgent advances in the medical field. New insights in thyroid cancer biology propelled the development of targeted therapies for this disease, including the tyrosine kinase inhibitor sorafenib as salvage treatment for DTC. In 2015, the US Food and Drug Administration approved a second tyrosine kinase inhibitor, lenvatinib, for the treatment of radioiodine-refractory thyroid cancer. Although associated with a significant progression-free survival improvement as compared to placebo in a large Phase III study (median progression-free survival 18.2 vs 3.6 months; hazard ratio 0.21; 99% confidence interval 0.14–0.31; P<0.001), the benefit of lenvatinib needs to be proved in the context of associated moderate to severe toxicities that require frequent dose reduction and delays. This article reviews the evidence supporting the use of lenvatinib as salvage therapy for radioactive iodine-refractory thyroid cancer, with a focus on the toxicity profile of this new therapy.

Keywords: lenvatinib, thyroid cancer, targeted therapy, differentiated thyroid cancer, tyrosine kinase inhibitor

Introduction

According to the Surveillance Epidemiology and End Results (SEER) database, the incidence of thyroid cancer, the most prevalent endocrine malignancy, increased in the US between 1975 and 2012, with estimated 62,450 new cases and 1950 deaths in 2015.1 A rising incidence has also been documented in many other countries.2 The most common types of thyroid cancer arise from follicular cells, which include papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). These subtypes account for 90%–95% of all cases and are collectively referred to as differentiated thyroid cancers (DTCs).2 In general, these are indolent tumors associated with a favorable prognosis as reflected by long-term survival rates of ~90% with standard treatments of surgery and radioactive iodine therapy.4 Nevertheless, patients who develop recurrent or metastatic radioactive iodine refractory disease have 10-year survival rates of only 15%–20%.5

Before the advent of targeted therapies, chemotherapy was the only option for the treatment of patients with advanced thyroid cancer of follicular origin refractory to radioactive iodine.5 Doxorubicin (with its known cardiac and hematologic toxicities) alone or in combination with other compounds formed the backbone of palliative...
therapy for such patients. The oncogene pathway-driven approach to the understanding of the pathophysiology of thyroid cancer led to the development of clinical trials that assessed the antitumor activity of tyrosine kinase inhibitors (TKIs). These studies provided evidence of clinically meaningful antitumor activity that is not seen with chemotherapy and ultimately supported the US Food and Drug Administration’s (FDA) approval of vandetanib and cabozantinib for the treatment of medullary thyroid cancer (MTC) and, more recently, sorafenib and lenvatinib for progressive radioiodine-refractory PTC and FTC. Notwithstanding their progression-free survival (PFS) benefit, TKIs are associated with significant and unique toxicity profiles. Furthermore, the decision of when to start treatment with a TKI can be challenging when encountering asymptomatic patients with slowly progressive radioiodine-refractory thyroid carcinomas, a relatively common finding in this disease. This article aims to critically review the data on antitumor activity, toxicity, and potential patient selection tools for the newly approved multikinase inhibitor lenvatinib.7

**Multikinase inhibitors approved for the treatment of follicular origin thyroid carcinomas**

A better understanding of the molecular biology of malignancies and the advent of targeted therapies represented an unprecedented development in the therapy of several solid tumors in recent years, including non-small-cell lung cancer, breast cancer, melanoma, and gastrointestinal stromal tumors. A comprehensive genetic analysis of 496 samples of PTC as part of the Cancer Genome Atlas (TCGA) project showed that driver genomic alterations were found in ~97% of cases. The vascular endothelial growth factor receptor (VEGFR) was one of the first signaling pathways to be associated with the aggressiveness of thyroid cancer. Despite its key role in the pathophysiology of thyroid malignancies, other signaling pathways drive the thyroid cancer cell behavior. Fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), v-ras oncogene homologue (RAS), B-raf proto-oncogene, serine/threonine kinase (BRAF), and RET/PTC rearrangement receptor, among others, have been recognized as important signaling pathways that are implicated in the pathophysiology of thyroid tumors. Until recently, sorafenib was the only kinase inhibitor approved by the US FDA for the treatment of metastatic iodine-refractory DTC. Sorafenib is an oral TKI that abrogates signaling from numerous molecules including BRAF, RET/PTC, VEGFR1–3, PDGFR, and c-KIT. The antineoplastic activity of sorafenib for the treatment of thyroid cancer was demonstrated in many trials including the DECISION trial, which was a Phase III placebo-controlled randomized study of 417 patients with progressive radioactive iodine-refractory, locally advanced, or metastatic thyroid cancer assigned to sorafenib 400 mg twice daily or placebo. The histological subtypes, confirmed by a central review, primarily consisted of PTC and FTC. The primary end point of the study was met with a hazard ratio (HR) for PFS of 0.59 (95% confidence interval [CI] 0.45–0.76; P<0.0001). The overall survival (OS) difference did not meet statistical significance, likely due to a crossover effect (HR 0.80; 95% CI 0.54–1.19; P=0.14). These benefits were counterbalanced by frequent treatment-related adverse events (AEs) including hand–foot syndrome (HFS), diarrhea, alopecia, and rash, which were documented in ~70% of the participants. Serious AEs occurred in 37% of patients treated with sorafenib compared to 26% of those treated with placebo. The most common treatment-related grade 3 AEs in the sorafenib arm included HFS (20%), diarrhea (5%), skin rash or desquamation (4.8%), fatigue (5%), and weight loss (5.8%). Dose modifications because of adverse effects were required in ~60% of the patients, and the treatment was suspended in 18% of the patients. HFS was the most frequent AE leading to dose modifications. These results are consistent with the toxicity profile of sorafenib observed in other malignancies.

Most recently, a meta-analysis of 24 Phase II and III trials estimated the risk of all-grade HFS at 39% for patients treated with sorafenib. Prophylactic treatment with urea-based cream can decrease the incidence of or delay the development of HFS in patients receiving sorafenib. Another meta-analysis showed that all-grade diarrhea occurred in 37% of patients treated with sorafenib for different types of tumors and can negatively impact quality of life.

In addition to sorafenib, several other kinase inhibitors have been studied for the treatment of advanced follicular origin radioiodine-refractory thyroid cancer (Table 1).

**Lenvatinib: overview**

Lenvatinib is a TKI that targets VEGFR1–3, FGFR1–4, PDGFR-α, RET, and c-KIT. Preclinical evidence indicates that lenvatinib inhibits tumor growth, tumor-induced angiogenesis, cell migration, and invasion in various human thyroid cancer xenograft and in vitro models. Compared to the other multikinase inhibitors tested in patients with differentiated thyroid tumors, lenvatinib is particularly active against the FGFR family of tyrosine kinase receptors.
## Lenvatinib for the treatment of advanced thyroid cancer

### Table 1 Kinase inhibitors studied and not yet US FDA approved in radioactive iodine-refractory thyroid tumors of follicular origin

<table>
<thead>
<tr>
<th>Drug</th>
<th>Histology (descending order in frequency)</th>
<th>Study phase (n)</th>
<th>ORR (%)</th>
<th>PFS (months)</th>
<th>Toxicity common all-grade AEs (descending order in frequency)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunitinib</td>
<td>PTC, FTC, Hürthle cell carcinoma, and MTC</td>
<td>II (35)</td>
<td>31</td>
<td>12.8</td>
<td>Neutropenia, leukopenia, fatigue, diarrhea, HFS</td>
</tr>
<tr>
<td>Axitinib</td>
<td>PTC, FTC, medullary, anaplastic</td>
<td>II (60)</td>
<td>30</td>
<td>18.1</td>
<td>Fatigue, diarrhea, nausea, anorexia, hypertension, stomatitis, weight loss, and headache</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>FTC, PTC, and Hürthle cell carcinoma</td>
<td>II (37)</td>
<td>49</td>
<td>11.7</td>
<td>Fatigue, hair and skin hypopigmentation, diarrhea, nausea, vomiting, anorexia, hypertension, and AST/ALT elevations</td>
</tr>
<tr>
<td>Motesanib</td>
<td>PTC, Hürthle cell carcinoma, and FTC</td>
<td>II (93)</td>
<td>14</td>
<td>10</td>
<td>Diarrea, hypertension, fatigue, weight loss, abdominal pain, nausea, anorexia, headache, dry mouth, and hypothyroidism</td>
</tr>
<tr>
<td>Cabozantinib</td>
<td>FTC, PTC, and Hürthle cell carcinoma</td>
<td>I (15)</td>
<td>53</td>
<td>Not reached for median follow-up of 12.2 months</td>
<td>Diarrea, hypertension, decreased appetite, and fatigue</td>
</tr>
<tr>
<td>Vandetanib</td>
<td>PTC, FTC, and poorly differentiated carcinoma</td>
<td>II (145)</td>
<td>8</td>
<td>11.1</td>
<td>Diarrhea, hypertension, acne, asthenia, decreased appetite, rash, QTc prolongation</td>
</tr>
<tr>
<td>Vemurafenib</td>
<td>FTC only</td>
<td>II (51)</td>
<td>35–26&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15.6–6.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Rash, fatigue, weight loss, and increased bilirubin</td>
</tr>
<tr>
<td>Dabrafenib</td>
<td>Well differentiated (not specified), poorly differentiated carcinoma, FTC, oncocytic, and Hürthle cell features&lt;sup&gt;a&lt;/sup&gt;</td>
<td>II (14)</td>
<td>29</td>
<td>11.3</td>
<td>Skin papillomas, hyperkeratosis, alopecia, arthralgia, hair texture abnormality, pyrexia, seborrheic keratosis, and skin hypertrophy</td>
</tr>
<tr>
<td>Selumetinib</td>
<td>PTC and poorly differentiated carcinoma</td>
<td>II (20)</td>
<td>25&lt;sup&gt;a&lt;/sup&gt;</td>
<td>35% of patients had disease controlled for at least 6 months&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>Fatigue, maculopapular rash, acneiform rash, AST and ALT elevations</td>
</tr>
</tbody>
</table>

**Notes:** <sup>a</sup>In 60% of patients, iodine<sup>124</sup> uptake increased after selumetinib therapy; partial responses were observed in 20% (5/20) of patients treated with both iodine<sup>124</sup> and selumetinib; <sup>b</sup>35% (7/20) of the patients who received both therapeutic iodine and selumetinib had sustained partial and stable disease for at least 6 months; *all BRAF-mutated tumors; **best results were seen in the TKi-naïve patient group compared to the TKi-exposed group.

**Abbreviations:** FDA, Food and Drug Administration; ORR, overall response rate; PFS, progression-free survival; AEs, adverse events; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; HFS, hand–foot syndrome; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TKI, tyrosine kinase inhibitor; QTc, ; PET-CT, .
FGFRs contain three immunoglobulin-like extracellular domains, a transmembrane region, and an intracellular domain, which is composed of a split tyrosine kinase and its carboxyterminus. FGFRs are overexpressed in a variety of solid tumors, including thyroid cancer. Preclinical models and immunohistochemistry analyses of tumor tissues showed that FGFR1 is overexpressed in 50%–75% of cells in both follicular and papillary tumors. FGFR2 seems to be expressed in normal thyroid tissues but not in tumors. FGFR3 is overexpressed in 25%–50% of well-differentiated follicular origin thyroid cancers. Cells and xenograft models were treated with the TKI PD173074, which is known to selectively inhibit FGFR phosphorylation and tyrosine kinase activity in solid tumors. The abrogation of FGFR1 and 3 signaling with PD173074 was associated with in vitro and in vivo growth inhibition of differentiated thyroid tumor cell lines. TPC-1 cells sustained up to 90% inhibition of cell proliferation, and xenograft models treated with PD173074 achieved a tumor size reduction of ~55%. These observations indicate the importance of the FGFR pathway in thyroid cancer pathogenesis and progression.

Next-generation sequencing analysis of the genomes of 492 samples of PTC identified this disease as having a low mutational burden compared with other carcinomas. FGFR3 amplification was noted in only one case, and FGFR2 gene fusions were observed in only two cases. Evidence supports that FGFR overexpression is regulated through epigenetic modulation.

Clinical efficacy and toxicity of lenvatinib

In a dose-escalation 3+3 Phase I trial, the maximum tolerated dose (MTD) of lenvatinib was investigated among a wide range of doses (0.5–20 mg twice daily) in solid tumors, including colon, sarcoma, and non-small-cell lung cancers. Dose-limiting toxicities of grade 3 elevations of aspartate and alanine aminotransferases and thrombocytopenia were observed at the 20 mg twice-daily dose level. MTD was 13 mg twice daily on a 2-week-on/1-week-off schedule for this trial. Of note, five patients experienced six serious AEs related or possibly related to the study drug. A larger Phase I trial investigated the safety and efficacy of lenvatinib among 82 patients with advanced refractory solid tumors, which included renal, colorectal, and pancreatic tumors. Lenvatinib was well tolerated at 25 mg daily. Grade 3 hypertension and proteinuria occurred in nine patients (11%) and six patients (7%), respectively. A positive correlation between the dose of lenvatinib and hypertension and proteinuria was observed. In the expanded MTD cohort of 25 mg (n=24), grade 3 hypertension occurred in three (13%) patients and grade 3 proteinuria in two (8%) patients.

Based on these Phase I trial results, a subsequent Phase II trial was conducted among 58 patients with differentiated radiiodine-refractory thyroid cancer who were treated with lenvatinib at 24 mg daily. Prior anti-VEGFR therapy and chemotherapy were reported in 29% and 14% of the patients, respectively. There was a response rate of 50% and a median PFS of 12.7 months. AEs led to dose interruptions, reductions, or study drug withdrawal in 74%, 66%, and 26% of the patients, respectively. Grade 3 or higher AEs occurred in 72% of the patients. The most common grade 3 side effects were weight loss (12%), hypertension (10%), proteinuria (10%), diarrhea (10%), fatigue (9%), dehydration (9%), and arthralgia (5%). Of note, two patients died after serious AEs (one arterial hemorrhage and one cardiac arrest).

In another cohort of patients, lenvatinib was tested at the set dose of 24 mg daily in 59 patients with advanced refractory well-differentiated radioiodine-refractory thyroid cancer who were treated with lenvatinib at 24 mg daily. Prior anti-VEGFR therapy and chemotherapy were reported in 29% and 14% of the patients, respectively. There was a response rate of 50% and a median PFS of 12.7 months. AEs led to dose interruptions, reductions, or study drug withdrawal in 74%, 66%, and 26% of the patients, respectively. Grade 3 or higher AEs occurred in 72% of the patients. The most common grade 3 side effects were weight loss (12%), hypertension (10%), proteinuria (10%), diarrhea (10%), fatigue (9%), dehydration (9%), and arthralgia (5%). Of note, two patients died after serious AEs (one arterial hemorrhage and one cardiac arrest).

### Table 2 Kinase inhibitors studied in radioiodine-refractory PTC and FTC and their targets

<table>
<thead>
<tr>
<th>TKI</th>
<th>VEGFR</th>
<th>RET</th>
<th>c-KIT</th>
<th>PDGFR</th>
<th>FGFR</th>
<th>BRAF</th>
<th>EGFR</th>
<th>MET</th>
<th>FLT3</th>
<th>MEK1</th>
<th>MEK2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lenvatinib</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sorafenib</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunitinib</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axitinib</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pazopanib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motesanib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cabozantinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vandetinib</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabrafenib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Selumetinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Vemurafenib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

**Abbreviations:** PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast growth factor receptor; EGFR, epidermal growth factor receptor; FLT3, FMS-like tyrosine kinase 3.
MTC, 44% of whom received prior anti-VEGFR therapy and 15% received prior chemotherapy. Overall response rate (ORR) was 36%, and median PFS was 9 months. Dose reduction or interruption was necessary in up to 59% of the patients, and 24% of the patients discontinued treatment due to AEs. The most common grade 3 side effects included diarrhea (14%), hypertension (7%), decreased appetite (7%), fatigue (5%), dysphagia (5%), and increased levels of alanine aminotransferase (5%). Overall, 3 AEs occurred in 36 patients (61%). There were three deaths due to AEs including respiratory arrest (not otherwise specified), respiratory failure, and paraneoplastic syndrome (not specified); only the respiratory failure-related death was deemed to be related by the treating physicians.

In the seminal Phase III study SELECT, a total of 392 patients with radioactive iodine-resistant progressive thyroid carcinomas of follicular origin (defined as progression within the previous 13 months according to Response Evaluation Criteria In Solid Tumors, the presence of one measurable lesion without radioiodine uptake on any 131Iodine scan, or disease progression within 12 months of radioiodine therapy) were randomized to either lenvatinib (n = 261) or placebo (n = 131). A significant improvement in the median PFS, the primary end point, was documented among patients treated with lenvatinib compared to placebo (18.3 vs 3.6 months; HR 0.21; 99% CI 0.14–0.31; P < 0.001), with an unprecedented response rate of 64.8%. Ninety-three patients in the trial received prior anti-VEGF TKIs (sorafenib 77%, sunitinib 9%, pazopanib 5%, and other 9%). Despite the previous use of targeted therapies, lenvatinib also significantly improved the PFS in this subgroup of patients (15.1 vs 3.6 months; HR 0.22; 95% CI 0.12–0.41) and increased response rates (62.1 vs 3.7%). Complete radiologic responses were seen in four patients, and prolonged stable disease (longer than 23 weeks) was noted in 39 patients treated with lenvatinib. While consistent with the results of Phase I and II studies, the toxicity profile in this study was significant.

As noted with the use of other multikinase inhibitors, lenvatinib toxicity resulted in a significant rate of dose adjustments and clinically relevant consequences. Grade 3 or higher toxicities were seen in 75% of the patients. Dose reductions, dose interruptions, and treatment discontinuation were needed in 67%, 82%, and 14% of the patients, respectively. The most frequent grade 3 or higher treatment-related AEs were hypertension (42%), fatigue (9%), diarrhea (8%), proteinuria (10%), arterial and venous thromboembolic effects (2.7% and 3.8%, respectively), acute renal failure (1.9%), and hepatic failure (0.4%). Dose modifications due to severe diarrhea and decreased appetite were required in 22% and 18% of the patients, respectively. In this larger trial, QTc prolongation was seen in 8% of the patients, of whom 1.5% experienced grade ≥3 AEs, defined as a QTc ≥501 ms. However, among a study of healthy individuals who took a single 32 mg dose of lenvatinib, there was a lack of QTc prolongation within the 24-hour continuous electrocardiogram (EKG) monitoring period. Thus far, there seems to be no evidence of significant direct cardiac toxicity associated with lenvatinib.

Of note, six deaths in the lenvatinib group were considered treatment related: three cases resulted from unspecified causes and three were associated with pulmonary embolism, hemorrhagic stroke, and health deterioration. However, four of these deaths were nonspecific in etiology, and it is thus difficult to accurately assess the contribution of lenvatinib toxicity to these fatal events.

As of yet, data on median OS are not available, and no significant OS benefit has been demonstrated with lenvatinib thus far (HR 0.73, 95% CI 0.5–1.0; P = 0.10). Notably, 109 patients per protocol were allowed to cross over to the lenvatinib arm upon disease progression, which can confound differences in OS. As of November 2013, 130 patients received blinded treatment. Nonetheless, an updated survival data analysis of the SELECT trial at a later cut-off date (June 15, 2014) was presented at the 2015 European Cancer Congress. To adjust for the crossover and estimate the true OS treatment effect (the effect that would have been observed in the absence of switching), a rank-preserving structural failure time model was used. After 34 months of follow-up of the trial for the lenvatinib arm, the median OS was not reached for this group. For the placebo crossover arm, the reported median OS was 19.1 months (95% CI 14.3, not estimable). The rank-preserving structural failure time-adjusted HR showed a significant difference in OS between the treatment groups (HR 0.53; 95% CI 0.34–0.82; nominal P = 0.0051) as determined using the resampling method (bootstrapping).

Of note, hypertension was the most common grade 3 or higher toxicity, affecting 42% of the patients in the SELECT trial, while observed in only 7%–10% of the patients in the Phase II trials. All-grade hypertension occurred in up to 67% of the patients treated with lenvatinib (SELECT), and it led to dose reductions or interruptions in up to 20% of the patients. In the Phase II trials, hypertension was observed in 51%–76% of the patients treated with lenvatinib. Because of the risk of hypertension, careful cardiovascular evaluation of patients, including performing an echocardiogram and EKG profile, should be considered prior to initiation of therapy. An EKG should also be performed prior to initiation of therapy, considering the risk of QTc prolongation associated with multikinase inhibitors in general.
Frequent blood pressure monitoring should be performed throughout treatment. According to the SELECT study protocol, dose interruptions of up to 28 days for patients with grade ≥2 hypertension should be performed prior to dose reduction (20, 14, 10 mg/d). Patients with confirmed systolic blood pressure (BP) ≥140 mmHg or diastolic BP ≥ 90 mmHg should be prescribed antihypertensive agents and monitored every 2 weeks. Patients with systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg, despite optimal management, should have a dose reduction.

In the Phase III SELECT study, gastrointestinal perforation or fistula was observed in 2% of patients receiving lenvatinib compared to 0.8% in the placebo group. In addition, aerodigestive fistula formation had also been documented in a case report in which a patient receiving lenvatinib developed significant general decline and required percutaneous gastrostomy for nutritional support. Radiation therapy and large thoracic tumor burden are considered risk factors for aerodigestive fistula formation associated with lenvatinib and other anti-angiogenesis therapies. Hemorrhagic complications were also documented in the 35% of patients treated with lenvatinib in the Phase III trial compared to 18% in the placebo group. Epistaxis was the most common hemorrhagic event (11% grade 1 and 1% grade 2). The incidence of severe hemorrhage episodes (grade 3–5) was comparable between both the groups (2% lenvatinib and 3% placebo). One patient with brain metastases at baseline treated with lenvatinib died from intracranial hemorrhage. These results are in agreement with the risk of fatal bleeding documented with other tyrosine kinase inhibitors and highlight the importance of careful monitoring. The clinically meaningful benefit in PFS and tumor response rate in this disease setting led to the US FDA’s approval of lenvatinib in February 2015 for the treatment of progressive thyroid cancer.

**Potential predictive biomarkers for lenvatinib efficacy**

Despite the overall response rate of >60% across distinct histologic subtypes (ie, papillary, poorly differentiated, follicular, and Hürthle cell), up to 35% of the patients did not meet criteria for response under the therapy with lenvatinib. This is particularly important in patients who are symptomatic from their tumor burden and would benefit from tumor reduction. Also, as described earlier, lenvatinib has been associated with significant toxicity and treatment-related deaths. Hence, it is paramount to find predictive markers of response, which may facilitate selecting patients for therapy.

The first and best-characterized point mutation in thyroid cancer is a valine-to-glutamate substitution at residue 600 (V600E) of the \( {\text{BRAF}} \) (v-raf murine sarcoma viral oncogenes homolog B1) gene. This results in constitutive activation of the \( {\text{BRAF}} \) kinase that confers continuous activation of the mitogen-activated protein kinase (MAPK) signaling pathway with consequent uncontrolled cell growth. \( {\text{BRAF}} \) mutations may have prognostic value in differentiated thyroid tumors. A recent retrospective analysis of 500 patients with PTC showed tumor recurrence rates of 25% among those with a \( {\text{BRAF}} \) V600E mutation as compared to 9.6% in mutation-negative patients.

Following \( {\text{BRAF}} \) mutations in thyroid cancers (40%), the most frequent driver mutations occur in the \( {\text{RAS}} \) genes. There are three isoforms of \( {\text{RAS}}: {\text{HRA}}, {\text{KRA}}, \) and \( {\text{NRRA}}. \) The most common \( {\text{RAS}} \) mutations in thyroid cancer occur in the \( {\text{NRRA}} and {\text{HRA}} \) genes and lead to constitutive activation of both the MAPK and phosphoinositide 3-kinase (PI3K)/AKT pathways. \( {\text{RAS}} \) can be mutated in up to 20% of FTC and in 6%–13% of patients with PTC. Archival formalin-fixed, paraffin-embedded tissues were obtained and analyzed for \( {\text{BRAF}} \) and \( {\text{RAS}} \) mutation hotspots in the SELECT trial. Interestingly, the benefit of lenvatinib was independent of the \( {\text{BRAF}} \) and \( {\text{RAS}} \) mutational status of the tumor on a preplanned subgroup analysis in SELECT. This could be due to the wide range of tumor cell targets affected by lenvatinib or its ability to target unique molecules such as the FGFR.

The angiogenesis of MTC, a highly vascular tumor, is mediated principally by VEGF, FGF, PDGF, and their respective receptors. Overexpression of VEGF and VEGFR2 has been observed in 50%–95% of MTC tumors and is associated with metastases. In the aforementioned Phase II trial of lenvatinib for the treatment of 59 patients with advanced MTC, in which circulating cytokine and angiogenic factors levels were collected from 51 patients after 8 days of therapy, high baseline levels of VEGF, soluble VEGFR3, and PDGF-β, and low baseline levels of soluble Tie-2 were associated with tumor reduction. Low baseline levels of angiopoietin-2 (Ang-2), hepatocyte growth factor, and interleukin-8 were associated with tumor reduction and prolonged PFS. In the SELECT trial, which accrued patients with FTC and PTC, blood cytokine and angiogenic factor levels of 99% of patients were collected on cycle 1, day 15 and day 1 of subsequent cycles. Ang-2 and sTie-2 levels were consistently decreased throughout the therapy with lenvatinib when compared with the placebo group. Decreased Ang-2 and sTie-2 levels along with increased VEGF levels correlated with tumor shrinkage; at the end of the treatment, the levels of these two molecules on C2D1
increased in 78.9% and 81% of patients, respectively.60 The association between lenvatinib benefit or lack thereof and baseline angiogenic factors merits further investigation before it can affect patient treatment selection.

Finally, in light of lenvatinib-related toxicity, the possible interaction between age and therapy with lenvatinib was formally explored for OS end point in the SELECT trial. Improved OS was identified in patients older than 65 years (median 71 years) when treated with lenvatinib.67

Discussion
At this juncture, the antitumor activity of lenvatinib, including its improvement in PFS, among patients with advanced progressive thyroid carcinomas of follicular origin supports its clinical use. Recently published guidelines by the American Thyroid Association and the National Comprehensive Cancer Network recommend its possible use in patients with radioiodine-refractory progressive thyroid carcinomas and as first-line kinase inhibitor therapy.68,69

Thus far, no other multikinase inhibitors have displayed a comparable degree of efficacy in the treatment of advanced radioiodine-refractory thyroid cancer. Taking into account all of the caveats inherent to cross-trial comparisons, the US FDA approved the TKI sorafenib based on the results of the DECISION trial, which showed a PFS of 10.8 months in the sorafenib arm vs 5.8 months in the placebo arm (HR 0.59; 95% CI 0.45–0.76; P<0.0001) and an ORR of 12.2%.27 By contrast, lenvatinib-treated patients derived a greater benefit from this TKI compared to placebo in the SELECT trial, as reflected by a PFS of 18.3 months vs 3.6 months (HR 0.21; 99% CI 0.14–0.31; P<0.001) and an ORR of 64.8%.37 Both these trials included similar patient populations, but the DECISION trial excluded patients with previous TKI exposure. The SELECT trial included 93 patients who had received prior TKI therapy (sorafenib 77%, sunitinib 9%, pazopanib 5%, other 9%). The benefit of lenvatinib was not mitigated by prior multikinase treatment.48 One could hypothesize that the remarkable antitumor activity of lenvatinib is due to its tyrosine kinase inhibition of FGFR.19 FGFR family activation leads to upregulation of the RAS/MAPK and PI3K/AKT signaling pathways.70 FGFR overexpression and phosphorylation observed in preclinical studies suggest that FGFR is an important signaling pathway in the thyroid tumors of follicular origin, as reviewed earlier.19

Despite its efficacy, the toxicity of lenvatinib merits cautious consideration. Up to 65%–71% of the patients treated with lenvatinib experienced grade 3 or higher toxicities, having warranted dose reductions and/or delays in the majority of the patients in previous Phase II and III clinical trials (Table 3).45-47 The pattern of disease progression in radioiodine-refractory thyroid tumor should also be considered at the time of therapy initiation (median PFS in placebo-treated groups range from 3.6–5.8 months) to the extent that asymptomatic patients may take months to meet criteria for disease progression. Hence, the potential for antitumor efficacy needs be carefully counterbalanced against its potential toxicities in asymptomatic patients prior to drug initiation. Lenvatinib should be initiated at the time of rapid radiological/clinical disease progression and in the setting of symptomatic tumor burden. Furthermore, patients need to be carefully selected for lenvatinib therapy, and physicians should be aware of the frequency of moderate to severe AEs, including hypertension, weight loss, decreased appetite, and proteinuria associated with this medication (Table 3).

Finally, careful consideration of locally directed therapies (eg, surgery, radiation therapy, thermal ablation) should be given prior to initiation and during the course of treatment with lenvatinib.68,69 This is of particular importance in the setting of mixed responses in distinct metastatic sites with imminent risk of complications related to local progression and invasion of metastasis (Figure 1).

Formal quality of life assessments were not reported for the SELECT trial, but sorafenib-treated patients in the DECISION trial had lower on-treatment scores for the Functional Assessment of Cancer Therapy: General, EuroQol-5D and EuroQol-5D visual analog scales, suggesting a detectable negative impact of sorafenib therapy on health-related quality of life.71 Nonetheless, in light of the toxicity profile, the corollary is that physicians need to be fully aware and aggressively treat eventual AEs to maintain quality of life.

The role of lenvatinib as salvage therapy for patients with previous exposure to TKIs, such as sorafenib, is a question of clinical relevance. A retrospective analysis of 17 patients with sorafenib-refractory thyroid cancer treated with salvage therapy, including sunitinib (n=4), pazopanib (n=3), cabozantinib (n=4), lenvatinib (n=3), and vemurafenib (n=3), revealed an ORR of 41% and a median PFS of 11.4 months.72 This suggests that TKIs with different targets may still be effective for refractory disease. These results are consistent with a subgroup analysis of the SELECT trial in which patients who had been previously exposed to TKIs still derived benefit from lenvatinib.45 Patients with a history of previous exposure to TKIs had an ORR of 65.6%, whereas TKI-naïve patients had an ORR of 62.1%.

The question of whether lenvatinib or sorafenib should be the first option for first-line treatment of patients with
iodine-refractory DTC still remains. The lack of head-to-head comparison of these molecules generates the need for constant individualized decision making, taking into account the estimated efficacy and toxicity for each multikinase inhibitor.

There is no biomarker that facilitates the selection of or the prediction of response to lenvatinib. Stratified analysis of pre-therapy BRAF and RAS mutational status failed to show a predictive benefit of these tests in Phase III trials of sorafenib and lenvatinib.27,47

Simultaneous targeting of multiple molecular pathways is a potential strategy to improve the antitumor activity of lenvatinib and to potentially increase the efficacy of and delay resistance to lenvatinib therapy in radioiodine-refractory thyroid cancer. The combined analysis of genomic variants, gene expression, and methylation patterns of 496 samples of PTC was able to cluster this tumor into two main molecular signature groups: the BRAF-mutant and the RAS-mutant tumors with differential downstream pathway activation of MAPK and PI3K/AKT, respectively.14 One could hypothesize that lenvatinib’s efficacy could be further increased by treatment combinations driven by pathway-enriched patient selection according to differential tumor signatures. The development of the combination treatment with the MEK inhibitor trametinib and the BRAF inhibitor dabrafenib in recurrent thyroid cancer is ongoing (NCT01723202).73 However, to our knowledge, the multiple pathway blockade approach with lenvatinib is nonexistent at this time.

Also, hepatocyte growth factor (HGF) and Met are overexpressed in the majority of PTCs (≥90%), but rarely in FTCs.74 HGF overexpression correlates with invasiveness and a more clinically aggressive behavior of PTCs.75–77 The Met receptor is a key component of HGF pathobiology in PTC.78 Among PTC cell lines, the Met inhibitor PHA665752 inhibited tumor cell growth and induced apoptosis.79 Interestingly, preclinical data indicate that one of the mechanisms of intrinsic lenvatinib therapy resistance is mediated by HGF pathway activation in various solid tumors such as melanoma and pancreatic carcinoma.80 This can be circumvented by the combination of lenvatinib with the Met inhibitor golvatinib, which showed significant reduction of lenvatinib-resistant cell proliferation in vitro.80 A Phase I dose-escalation trial of the combination of lenvatinib and golvatinib in patients with melanoma and glioblastoma is currently under way (NCT01433991).81 Further studies are necessary to establish the role of Met inhibition in thyroid cancer.

Interestingly, the degree of toxicity from anti-endothelial growth factor receptor and anti-VEGF drugs has been

---

**Table 3** Lenvatinib Phase II and III trials toxicities profile

<table>
<thead>
<tr>
<th>Phase II and III studies</th>
<th>SELECT trial*</th>
<th>Phase II*</th>
<th>Phase IIIa*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>392</td>
<td>58</td>
<td>23</td>
</tr>
<tr>
<td><strong>Cohort</strong></td>
<td>Radioiodine-refractory thyroid cancer of follicular origin</td>
<td>Refractory medullary thyroid cancer</td>
<td>Radioiodine-refractory thyroid cancer of follicular origin</td>
</tr>
<tr>
<td><strong>Common clinical AEs</strong></td>
<td>Diarrhea, hypertension, fatigue, decreased appetite, nausea, vomiting, weight loss</td>
<td>Diarrhea, hypertension, decreased appetite, fatigue, dehydration, arthralgia</td>
<td>Diarrhea, hypertension, decreased appetite, fatigue</td>
</tr>
<tr>
<td><strong>Grade ≥3</strong></td>
<td>75%</td>
<td>26%</td>
<td>61%</td>
</tr>
<tr>
<td><strong>Discontinuation of medication due to AEs</strong></td>
<td>14%</td>
<td>26%</td>
<td>24%</td>
</tr>
<tr>
<td><strong>Dose reduction due to AEs</strong></td>
<td>67%</td>
<td>66%</td>
<td>59%</td>
</tr>
<tr>
<td><strong>Dose delay due to AEs</strong></td>
<td>82%</td>
<td>74%</td>
<td>75%</td>
</tr>
<tr>
<td><strong>Number of deaths on study</strong></td>
<td>6</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td><strong>Cause of death</strong></td>
<td>Three unspecified, one pulmonary embolism, one hemorrhagic stroke, one health deterioration</td>
<td>One cardiac arrest, one aortic hematom, one aneurysm</td>
<td>Two respiratory failures (one not specified), one paraneoplastic syndrome</td>
</tr>
</tbody>
</table>

Notes: Lenvatinib was administered at 24 mg po daily in 28-day treatment cycles. **Grade 3 proteinuria was present in 10% of patients in two of the trials described in the table and AEs are presented in descending order of frequency. Abbreviation:** AEs, adverse events.
positively correlated with their efficacy among patients with solid tumors including colorectal, lung, renal cell carcinoma, and head and neck.\textsuperscript{82,83} The degree of toxicity, namely hypertension and proteinuria, could serve as a surrogate biomarker of lenvatinib activity. It has been suggested that AEs such as worst grade proteinuria correlated with lenvatinib antitumor activity in a small Phase I dose-escalation clinical trial.\textsuperscript{84} To our knowledge, no stratified analysis of the efficacy of lenvatinib by toxicity has been reported.

In addition, dose reduction of TKIs positively correlated with clinical benefit in non-small-cell lung cancer and chronic myeloid leukemia.\textsuperscript{85–87} In clinical practice, it is tempting to adopt a dose reduction strategy to avoid lenvatinib-associated toxicities while offering patients effective treatment. Data are not yet available on the efficacy of dose-reduced treatment of advanced thyroid cancer with lenvatinib. The results of the expanded cohort program with lenvatinib for the treatment of radioiodine-refractory DTC with three different doses, 24, 20, and 14 mg daily will shed light into this important question (NCT02211222).\textsuperscript{88}

In conclusion, lenvatinib is a novel multikinase inhibitor that demonstrates significant responses and PFS benefit in the treatment of radioiodine-refractory DTC. Consistent with the current 2015 American Thyroid Association and the National Comprehensive Cancer Network guidelines, lenvatinib should be considered as the first-line therapy in the setting of clinically relevant disease progression and/or symptomatic disease burden in the setting of radioiodine-refractory disease, with the warning that physicians should be fully cognizant of its side effect profile, including potentially fatal toxicities (Figure 1).\textsuperscript{68,69} Aggressive monitoring and guideline-based management of toxicities similar to those utilized with other TKIs should be enforced to prevent decline in quality of life.\textsuperscript{89–91} Future studies should endeavor to establish biomarkers predictive of toxicity and efficacy of lenvatinib treatment in radioiodine-refractory thyroid tumors.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


52. Lenvima [package insert]. Eisai Inc. under license from Eisai R&D Management Co., Ltd.


68. Haugen BRM, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015.


81. ClinicalTrials.gov [database on the Internet]. E7050 in combination with E7080 in subjects with advanced solid tumors (dose escalation) and in subjects with recurrent glioblastoma or unresectable stage III or stage IV melanoma after prior systemic therapy (expansion cohort and phase 2). Accessed October 3, 2015.


